JAPAN’s Takeda Pharmaceuticals
has announced the acquisition of
US vaccine developer Inviragen, a
company specialising in innovative
vaccines for emerging infectious
diseases including dengue fever
and hand, foot and mouth disease.
The purchase price is an
upfront payment of $35m and
future payments of up to $215m
linked to the progress of clinical
development and achievement of
key commercial milestones.The above article was sent to subscribers in Pharmacy Daily's issue from 10 May 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 May 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.